- Home
- MLYS vs AUTL Comparison
MLYS vs AUTL Comparison
Compare MLYS & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MLYS | AUTL |
|---|---|---|
| Founded | 2019 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 431.2M |
| IPO Year | 2023 | 2025 |
Fundamental Metrics
Financial Performance| Metric | MLYS | AUTL |
|---|---|---|
| Price | $23.51 | $1.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $48.67 | $8.50 |
| AVG Volume (30 Days) | 1.1M | ★ 1.4M |
| Earning Date | 03-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.43 | 28.33 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | N/A | $669.62 |
| Revenue Next Year | N/A | $79.78 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $10.44 | $1.11 |
| 52 Week High | $47.65 | $2.70 |
Technical Indicators
Market Signals| Indicator | MLYS | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 30.24 | 38.42 |
| Support Level | $13.42 | $1.27 |
| Resistance Level | $31.09 | $1.52 |
| Average True Range (ATR) | 1.76 | 0.08 |
| MACD | -0.30 | -0.03 |
| Stochastic Oscillator | 11.34 | 1.43 |
Price Performance
Historical ComparisonAbout MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.